AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2960925 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 100
Study 2960925 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 100
Study 31039797 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-family therapy (MFT)
Number of subjects: 150
Study 31039797 — intervention group
Group type: COMPARATOR
Intervention: Systemic single-family therapy (SFT)
Number of subjects: 150
Study 27678469 — intervention group
Group type: EXPERIMENTAL
Intervention: LDU‐LV
Number of subjects: 147
Study 27678469 — intervention group
Group type: COMPARATOR
Intervention: LV
Number of subjects: 147
Study 27022659 — intervention group
Group type: EXPERIMENTAL
Intervention: Anoro Ellipta (vilanterol and umeclidinium bromide)
Number of subjects: 0
Study 27022659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22142537 — intervention group
Group type: EXPERIMENTAL
Intervention: SunshowerMedical home UV device, used daily for 6 minutes over 6 weeks
Number of subjects: 29
Study 22142537 — intervention group
Group type: COMPARATOR
Intervention: Hospital UVB treatment (Waldmann 85/UV21 lamps), twice a week for 6 weeks
Number of subjects: 29
Study 21456039 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 40 mg/day plus modafinil 400 mg/day (200 mg bid)
Number of subjects: 46
Study 21456039 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 40 mg/day plus placebo
Number of subjects: 46
Study 17692108 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Number of subjects: 43
Study 17692108 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin
Number of subjects: 43
Study 17692108 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 43
Study 16522393 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (metronidazole 250 mg and erythromycin 250 mg tid orally for 7 days prenatally, metronidazole 250 mg and ampicillin 500 mg q 4 hours during labor)
Number of subjects: 2433
Study 16522393 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 2433
Study 16522393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2433
Study 16522393 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics and Placebo
Number of subjects: 2433
Study 16522393 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected women
Number of subjects: 2433
Study 14514590 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonremovable fiberglass cast boot (n = 42)
Number of subjects: 93
Study 14514590 — intervention group
Group type: COMPARATOR
Intervention: Off‐loading shoes (n = 51)
Number of subjects: 93
Study 11126185 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT plus rTMS (one UL ECT on Day 1 and rTMS on the following 4 days)
Number of subjects: 22
Study 11126185 — intervention group
Group type: COMPARATOR
Intervention: ECT only (non-dominant unilateral ECT, 3 times per week for 2 weeks)
Number of subjects: 22
Study 8982890 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal block with 1.5 ml/kg of 0.2% bupivacaine (Group I)
Number of subjects: 16
Study 8982890 — intervention group
Group type: COMPARATOR
Intervention: Local infiltration of the surgical site with up to 1.2 ml/kg of 0.25% bupivacaine (Group 2)
Number of subjects: 16
Study 8982890 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal epidural block (Group I)
Number of subjects: 16
Study 8982890 — intervention group
Group type: COMPARATOR
Intervention: Local infiltration (Group 2)
Number of subjects: 16
Study 1735480 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian electrocautery + hMG
Number of subjects: 33
Study 1735480 — intervention group
Group type: COMPARATOR
Intervention: LH-RH-a + hMG
Number of subjects: 33
Study 6099055 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (0.3 mg/kg body wt.)
Number of subjects: 18
Study 6099055 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone (4 mg/kg body wt.)
Number of subjects: 18
Study 31697244 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-being mobile app (8-week program, 4 classes per week, 15-min guided practice)
Number of subjects: 490
Study 31697244 — intervention group
Group type: COMPARATOR
Intervention: Active control app (4 assessments per week, 20 min self-observation)
Number of subjects: 490
Study 30286755 — intervention group
Group type: EXPERIMENTAL
Intervention: IVR behavior support
Number of subjects: 301
Study 30286755 — intervention group
Group type: EXPERIMENTAL
Intervention: Human-delivered behavior support
Number of subjects: 301
Study 30286755 — intervention group
Group type: COMPARATOR
Intervention: IVR control condition
Number of subjects: 301
Study 30286755 — intervention group
Group type: EXPERIMENTAL
Intervention: SIPsmartER participants
Number of subjects: 301
Study 24882503 — intervention group
Group type: EXPERIMENTAL
Intervention: Child ADHD/ODD-like behavior
Number of subjects: 90
Study 24882503 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated adult ADHD symptoms
Number of subjects: 90
Study 24882503 — intervention group
Group type: EXPERIMENTAL
Intervention: Child ADHD/ODD-like behavior and adult ADHD symptoms interaction
Number of subjects: 90
Study 24882503 — intervention group
Group type: COMPARATOR
Intervention: Typical behavior (control)
Number of subjects: 90
Study 24882503 — intervention group
Group type: EXPERIMENTAL
Intervention: Observer-coded parenting and interparental communication
Number of subjects: 90
Study 23365258 — intervention group
Group type: EXPERIMENTAL
Intervention: Force channel to constrain hand motion to a straight line
Number of subjects: 0
Study 23365258 — intervention group
Group type: COMPARATOR
Intervention: No force channel
Number of subjects: 0
Study 21030232 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage II COPD
Number of subjects: 213
Study 21030232 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage III COPD
Number of subjects: 213
Study 21030232 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage IV COPD
Number of subjects: 213
Study 21030232 — intervention group
Group type: EXPERIMENTAL
Intervention: Exacerbation of respiratory symptoms
Number of subjects: 213
Study 21030232 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid conditions
Number of subjects: 213
Study 21030232 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital COPD patients
Number of subjects: 213
Study 21030232 — intervention group
Group type: COMPARATOR
Intervention: Population-based controls
Number of subjects: 213
Study 19104775 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 20 mg
Number of subjects: 33
Study 19104775 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 40 mg
Number of subjects: 33
Study 19104775 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 60 mg
Number of subjects: 33
Study 19104775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 19104775 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 33
Study 16843480 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming up (muscle warm-up protocol)
Number of subjects: 30
Study 16843480 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy controls)
Number of subjects: 30
Study 15281672 — intervention group
Group type: EXPERIMENTAL
Intervention: New pre-employment medical assessment system
Number of subjects: 352
Study 15281672 — intervention group
Group type: COMPARATOR
Intervention: Old pre-employment medical assessment system
Number of subjects: 352
Study 11495140 — intervention group
Group type: EXPERIMENTAL
Intervention: B‐HA
Number of subjects: 10
Study 11495140 — intervention group
Group type: EXPERIMENTAL
Intervention: NC‐HA
Number of subjects: 10
Study 11495140 — intervention group
Group type: COMPARATOR
Intervention: Comparison between B‐HA and NC‐HA
Number of subjects: 10
Study 9923060 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 250 mg twice daily
Number of subjects: 370
Study 9923060 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin 250 mg twice daily
Number of subjects: 370
Study 9923060 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil
Number of subjects: 370
Study 9923060 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 370
Study 9923060 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil and Clarithromycin
Number of subjects: 370
Study 9192156 — intervention group
Group type: EXPERIMENTAL
Intervention: Delton sealant
Number of subjects: 344
Study 9192156 — intervention group
Group type: EXPERIMENTAL
Intervention: Duraphat varnish
Number of subjects: 344
Study 9192156 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 344
Study 9192156 — intervention group
Group type: COMPARATOR
Intervention: Sealant vs Control
Number of subjects: 344
Study 9192156 — intervention group
Group type: COMPARATOR
Intervention: Varnish vs Control
Number of subjects: 344
Study 9192156 — intervention group
Group type: COMPARATOR
Intervention: Sealant vs Varnish
Number of subjects: 344
Study 2044903 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole (40 mg)
Number of subjects: 9
Study 2044903 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral omeprazole (80 mg)
Number of subjects: 9
Study 6266642 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with MER (methanol-extracted residue of bacillus Calmette-Guerin)
Number of subjects: 103
Study 6266642 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy without MER
Number of subjects: 103
Study 30835827 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage IBBR with acellular dermal matrix (ADM)
Number of subjects: 121
Study 30835827 — intervention group
Group type: COMPARATOR
Intervention: Two-stage IBBR
Number of subjects: 121
Study 27581586 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical dilatation of the cervix during cesarean section
Number of subjects: 447
Study 27581586 — intervention group
Group type: COMPARATOR
Intervention: No dilatation of the cervix during cesarean section
Number of subjects: 447
Study 26952289 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher urinary sulfate concentration
Number of subjects: 1004
Study 26952289 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary sulfate concentration
Number of subjects: 1004
Study 26952289 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up for 12 months
Number of subjects: 1004
Study 25124692 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported Employment
Number of subjects: 100
Study 25124692 — intervention group
Group type: COMPARATOR
Intervention: Traditional Vocational Rehabilitation
Number of subjects: 100
Study 22940119 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone once daily from the day after insemination until 12 weeks of pregnancy or for 14 days in non-pregnant women
Number of subjects: 290
Study 22940119 — intervention group
Group type: COMPARATOR
Intervention: No progesterone (unsupported cycles)
Number of subjects: 290
Study 20590478 — intervention group
Group type: EXPERIMENTAL
Intervention: SJW 300 mg
Number of subjects: 118
Study 20590478 — intervention group
Group type: EXPERIMENTAL
Intervention: SJW 600 mg
Number of subjects: 118
Study 20590478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 17566826 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal contrast CT
Number of subjects: 232
Study 17566826 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-contrast CT
Number of subjects: 232
Study 17566826 — intervention group
Group type: COMPARATOR
Intervention: Noncontrast enhanced CT
Number of subjects: 232
Study 16252285 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 20
Study 16252285 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 20
Study 16252285 — intervention group
Group type: EXPERIMENTAL
Intervention: Time after feeding
Number of subjects: 20
Study 12394765 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose intravesical BCG (120 mg)
Number of subjects: 26
Study 12394765 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose intravesical BCG (40 mg)
Number of subjects: 26
Study 12394765 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of intravesical BCG
Number of subjects: 26
Study 9783492 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (ACE inhibitor) alone or in combination with indapamide (diuretic)
Number of subjects: 6000
Study 9783492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6000
Study 8197045 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 1.0 g/day for 10 days
Number of subjects: 252
Study 2853457 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (16 mg daily)
Number of subjects: 50
Study 2853457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 2853457 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium
Number of subjects: 50
Study 29671166 — intervention group
Group type: EXPERIMENTAL
Intervention: Four construct intervention
Number of subjects: 317
Study 29671166 — intervention group
Group type: EXPERIMENTAL
Intervention: Single construct interventions
Number of subjects: 317
Study 27546740 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE)
Number of subjects: 71
Study 25919011 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Exposure Physical Therapy
Number of subjects: 56
Study 25919011 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 56
Study 22045098 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-GDP PDF
Number of subjects: 125
Study 22045098 — intervention group
Group type: COMPARATOR
Intervention: Conventional PDF
Number of subjects: 125
Study 22045098 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 125
Study 20420642 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone (n = 19)
Number of subjects: 38
Study 20420642 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group, n = 19)
Number of subjects: 38
Study 18783988 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing with p16-INK4A triage
Number of subjects: 24661
Study 18783988 — intervention group
Group type: COMPARATOR
Intervention: Conventional cytology
Number of subjects: 24661
Study 18783988 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing with p16-INK4A triage (5% or more stained cells deemed positive)
Number of subjects: 24661
Study 15879836 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg vardenafil
Number of subjects: 440
Study 15879836 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg vardenafil
Number of subjects: 440
Study 15879836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 440
Study 12507208 — intervention group
Group type: EXPERIMENTAL
Intervention: 5FU-based regimens
Number of subjects: 0
Study 12507208 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chemotherapy plus radiation therapy
Number of subjects: 0
Study 10507814 — intervention group
Group type: EXPERIMENTAL
Intervention: Icodextrin (Ico)
Number of subjects: 38
Study 10507814 — intervention group
Group type: COMPARATOR
Intervention: Glucose (Glu)
Number of subjects: 38
Study 10457792 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg once daily for 2 weeks, then increased to 10 mg once daily if diastolic blood pressure did not fall below 90 mmHg
Number of subjects: 20
Study 10457792 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 20
Study 1388003 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal indomethacin
Number of subjects: 56
Study 1388003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 6437954 — intervention group
Group type: EXPERIMENTAL
Intervention: Metergoline
Number of subjects: 8
Study 30284065 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg ovalbumin-derived protein hydrolysate (3 g/day)
Number of subjects: 75
Study 30284065 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 g/day)
Number of subjects: 75
Study 28646591 — intervention group
Group type: EXPERIMENTAL
Intervention: Monochloroacetic acid
Number of subjects: 0
Study 28646591 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 0
Study 28646591 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cryotherapy and salicylic acid
Number of subjects: 0
Study 27871759 — intervention group
Group type: COMPARATOR
Intervention: Basiliximab induction with low-dose tacrolimus, mycophenolate mofetil, and steroid maintenance therapy (arm A)
Number of subjects: 615
Study 27871759 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid corticosteroid withdrawal on day 8 after basiliximab induction (arm B)
Number of subjects: 615
Study 27871759 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid corticosteroid withdrawal on day 8 after rabbit ATG (arm C)
Number of subjects: 615
Study 27871759 — intervention group
Group type: COMPARATOR
Intervention: Control arm A (basiliximab induction)
Number of subjects: 615
Study 27871759 — intervention group
Group type: COMPARATOR
Intervention: Comparison of BPAR rates between arms
Number of subjects: 615
Study 27871759 — intervention group
Group type: COMPARATOR
Intervention: Comparison of post-transplantation diabetes incidence
Number of subjects: 615
Study 27871759 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient survival and censored graft survival
Number of subjects: 615
Study 27871759 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety parameters (infections, malignancies)
Number of subjects: 615
Study 24383930 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1 receptor antagonist (IL-1Ra) 500 mg bolus, then 10 mg/kg/hr infusion for 24 hours
Number of subjects: 13
Study 24383930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 22854400 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy density preload (0.97 kcal/g)
Number of subjects: 47
Study 22854400 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy density preload (0.57 kcal/g)
Number of subjects: 47
Study 22854400 — intervention group
Group type: COMPARATOR
Intervention: No preload consumed
Number of subjects: 47
Study 20689391 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention using a new PA questionnaire and accelerometry
Number of subjects: 0
Study 20689391 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 17097152 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol 5g three times-a-day (TID)
Number of subjects: 120
Study 17097152 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol 7.5g once daily (QD)
Number of subjects: 120
Study 17097152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 16109574 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole-based therapy (20 mg esomeprazole, 1000 mg amoxicillin, 500 mg clarithromycin twice daily for 7 days)
Number of subjects: 104
Study 16109574 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole-based therapy (20 mg omeprazole, 1000 mg amoxicillin, 500 mg clarithromycin twice daily for 7 days)
Number of subjects: 104
Study 16109574 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole-based therapy
Number of subjects: 104
Study 16109574 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole-based therapy
Number of subjects: 104
Study 16109574 — intervention group
Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 104
Study 12217302 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin
Number of subjects: 320
Study 12217302 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 320
Study 9469333 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 800 IU daily
Number of subjects: 120
Study 9469333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 7824138 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-hemisphere anesthesia (Wada test)
Number of subjects: 54
Study 2228634 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help/minimal intervention strategies for smoking cessation
Number of subjects: 0
Study 89336 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term protein restriction
Number of subjects: 0
Study 89336 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term energy restriction
Number of subjects: 0
Study 89336 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary protein changes
Number of subjects: 0
Study 89336 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary energy changes
Number of subjects: 0
Study 30953416 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-adhesive flowable composite (Vetise Flow, VF) with self-etching primer (SP)
Number of subjects: 84
Study 30953416 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional flowable composite (Clearfil Magesty Flow, CM) with self-etching primer (SP)
Number of subjects: 84
Study 30953416 — intervention group
Group type: COMPARATOR
Intervention: Conventional flowable composite (Clearfil Magesty Flow, CM)
Number of subjects: 84
Study 30953416 — intervention group
Group type: COMPARATOR
Intervention: Self-adhesive flowable composite (Vetise Flow, VF)
Number of subjects: 84
Study 28339996 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple P-Positive Parenting Program
Number of subjects: 107
Study 28339996 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 107
Study 25951307 — intervention group
Group type: EXPERIMENTAL
Intervention: MTAD
Number of subjects: 60
Study 25951307 — intervention group
Group type: COMPARATOR
Intervention: 1% NaOCl
Number of subjects: 60
Study 25951307 — intervention group
Group type: COMPARATOR
Intervention: Comparison of MTAD vs 1% NaOCl
Number of subjects: 60
Study 23756608 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label LDX (20-70 mg/day)
Number of subjects: 92
Study 23756608 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label LDX
Number of subjects: 92
Study 23756608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 23756608 — intervention group
Group type: EXPERIMENTAL
Intervention: LDX
Number of subjects: 92
Study 21700105 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal collagen crosslinking (CXL)
Number of subjects: 71
Study 21700105 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 71